ADC Therapeutics (ADCT) AI Stock Analysis

• Market Cap: $536.13M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: 6.35%
• EPS Growth: 39.57%
• Country: US
• Employees: 263
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 127,044,360
• 10 Day Avg. Volume: 2,177,579
• 30 Day Avg. Volume: 1,256,694
• PEG Ratio: 0.10
• Price to Book (P/B): -2.41
• Price to Sales (P/S): 5.51
• P/FCF Ratio: -3.17
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 8.61
• Enterprise Value/Gross Profit: 9.51
• Enterprise Value/Ebitda: -6.58
• 1Y Price Target: $8.00
• Price Target Upside: 89.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.87
• Revenue Forecast (FY): $80.79M

• Rating: 54 Neutral
• Price Target: $4.50 ▲(6.64% Upside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

Overall score is held back primarily by weak financial performance (persistent losses, negative equity, rising debt and ongoing cash burn). Offsetting this, technicals are relatively strong with price trading above key moving averages and positive MACD, while earnings updates and recent corporate actions improved runway and highlighted promising clinical data but do not eliminate near-term profitability and funding risks.

Positive Factors

Strong clinical efficacy

Robust response and complete response rates in LOTUS VII and investigator studies indicate ZYNLONTA’s strong clinical activity. High efficacy in targeted DLBCL/indolent lymphoma settings materially raises the odds of label expansion and durable market adoption if confirmatory trials succeed.

Extended cash runway

Fresh financing and roughly $292M in cash extend runway to at least 2028, materially reducing near-term refinancing pressure. This funding horizon allows the company to complete pivotal trials and commercial investments, improving execution visibility for medium-term revenue expansion efforts.

Very high gross margins

Sustained gross margins in the low-90% range imply highly favorable product economics for ZYNLONTA. If sales scale, this provides substantial operating leverage: incremental revenue would flow to the bottom line faster, helping close structural losses without altering core technology or manufacturing model.

Negative Factors

Negative equity

Negative shareholders’ equity combined with a large 2025 debt increase signals structurally stressed capitalization. This limits strategic flexibility, raises the cost and difficulty of refinancing, and increases likelihood of dilutive financing or restrictive covenants that can hamper long-term R&D and commercialization plans.

Persistent cash burn

Consistent negative operating and free cash flow, even with 2025 improvement, means ongoing reliance on external capital to fund operations. Over a multi-quarter horizon this raises dilution and execution risk, forcing trade-offs between clinical development, commercial investment, and potential business development.

Revenue volatility & concentration

Material revenue volatility and reliance on a single marketed asset leave growth concentrated on successful label expansion. The company reduced noncore programs and workforce to focus on ZYNLONTA, magnifying downside if pivotal trials or uptake in new indications underperform, limiting durable revenue diversification.

ADC Therapeutics Business Overview & Revenue Model

Company Description

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

How the Company Makes Money

ADC Therapeutics primarily makes money from (1) product revenue generated by sales of ZYNLONTA in markets where it is commercialized (recorded as net product sales after customary deductions such as discounts, rebates/chargebacks, and returns) and (2) collaboration and licensing-related revenue. Collaboration revenue can include upfront payments, payments for research or other services, and milestone payments earned upon achieving specified development, regulatory, or commercial objectives under partnership agreements; when applicable, the company may also earn royalties on a partner’s net sales of products covered by such agreements. The relative contribution of each stream depends on ZYNLONTA’s commercial performance and the timing/achievement of milestones and other deliverables under collaboration arrangements.

ADC Therapeutics Financial Statement Overview

Summary

Financial profile is high-risk: revenue has been volatile with a sharp decline in 2025 vs. 2024, losses remain large, and cash flow is consistently negative despite some improvement in 2025. Balance-sheet stress is the biggest concern, with negative equity since 2023 and a large increase in debt in 2025, implying elevated refinancing/dilution risk.

Income Statement

Revenue has been volatile—surging in 2022 but contracting materially afterward (2025 revenue down sharply vs. 2024). While gross margin remains very strong (low-90%+ in 2023–2025), the company continues to run heavy operating losses and deep net losses each year (2025 net margin roughly -194%), indicating the current cost structure is not supported by the revenue base. Losses have improved from the extreme levels seen in 2021 and 2023, but profitability remains a key weakness.

Balance Sheet

The balance sheet shows elevated financial risk: shareholders’ equity turned negative from 2023 onward, which limits flexibility and makes leverage look structurally stressed. Total debt increased dramatically in 2025 versus 2024, and with negative equity this raises refinancing and dilution risk. Total assets have been relatively stable, but negative equity and rising debt are significant red flags despite some year-to-year improvement in net loss versus 2023.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative across all years provided, indicating ongoing cash burn. Free cash flow improved meaningfully in 2025 versus 2024 (less negative), but it remains deeply negative overall. Cash burn roughly tracks reported losses (free cash flow to net income near 1x), which suggests limited non-cash cushioning and reinforces the need for external funding until operations improve.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	81.36M	70.84M	69.56M	209.91M	33.92M
Gross Profit	73.68M	64.89M	67.03M	206.61M	32.52M
EBITDA	-106.50M	-102.65M	-145.83M	-107.70M	-230.53M
Net Income	-142.62M	-157.85M	-240.05M	-157.13M	-230.03M
Balance Sheet
Total Assets	323.15M	321.98M	354.78M	490.86M	617.97M
Cash, Cash Equivalents and Short-Term Investments	261.34M	250.87M	278.60M	326.44M	466.54M
Total Debt	439.01M	123.00M	124.38M	129.85M	139.70M
Total Liabilities	508.98M	524.62M	503.03M	411.41M	451.88M
Stockholders Equity	-185.83M	-202.64M	-148.25M	79.45M	166.09M
Cash Flow
Free Cash Flow	-141.44M	-124.70M	-121.90M	-139.00M	-239.75M
Operating Cash Flow	-141.17M	-123.83M	-118.69M	-138.31M	-233.38M
Investing Cash Flow	395.00K	-867.00K	-3.22M	-687.00K	-6.67M
Financing Cash Flow	150.94M	97.05M	73.88M	-897.00K	267.39M

ADC Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADCT, the sentiment is Neutral. The current price of 4.22 is below the 20-day moving average (MA) of 4.27, above the 50-day MA of 3.95, and above the 200-day MA of 3.65, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 50.79 is Neutral, neither overbought nor oversold. The STOCH value of 24.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADCT.

ADC Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVIR	57 Neutral	$482.02M	-1.84	-46.34%	―	―	14.33%
ADCT	54 Neutral	$536.13M	-3.14	76.03%	―	6.35%	39.57%
JBIO	52 Neutral	$702.76M	-3.80	-50.23%	14.68%	―	89.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HRTX	48 Neutral	$169.16M	-10.73	304.91%	―	12.60%	58.23%
OLMA	47 Neutral	$1.31B	-4.97	-39.60%	―	―	17.23%
SLN	46 Neutral	$347.17M	-3.24	―	―	―	―

ADC Therapeutics Corporate Events

ADC Therapeutics Amends Royalty Deal, Issues New Warrants

On February 18, 2026, ADC Therapeutics amended its 2021 royalty-based funding agreement with entities managed by HealthCare Royalty Management, which have provided $300 million to the company. The amendment significantly revises the company’s change-of-control obligations, reducing the lump-sum payment due upon a takeover to $150 million if completed by the end of 2027 or $200 million thereafter, while allowing royalty obligations to continue unless bought out under a defined schedule.

Under the revised structure, ADC or a future acquirer may buy out remaining royalty obligations for $525 million if done by the end of 2029 or $750 million from 2030 onward, with prior royalties and any change-of-control payment credited against the buyout price. This reshaping of payment triggers alters the economics of a potential sale and could make the company a more flexible transaction partner, while preserving long-term royalty participation for the funding partner.

In connection with the amendment, ADC issued HealthCare Royalty warrants to purchase 9,834,776 common shares at an exercise price of $3.8130 per share, exercisable until December 31, 2030, with options for cash or cashless exercise and certain limits tied to the company’s treasury stock. The warrants include deemed exercise or assumption mechanics in the event of major corporate transactions and carry registration rights for the underlying shares, reinforcing HealthCare Royalty’s equity-linked exposure to ADC’s future performance.

The most recent analyst rating on (ADCT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.

ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy

On January 12, 2026, ADC Therapeutics released an updated corporate presentation highlighting its strategy to build growth around ZYNLONTA and strengthen its financial position following a year of portfolio derisking and cost restructuring in 2025. The company reported that preliminary full-year 2025 net revenue for ZYNLONTA was approximately $73 million, roughly in line with 2024, and detailed a strategic reprioritization that included discontinuation of its remaining solid-tumor preclinical pipeline, a roughly 30% global workforce reduction, and closure of its UK operations to concentrate resources on ZYNLONTA expansion. Clinical updates pointed to strong response rates in the LOTIS-7 trial and in investigator-initiated studies in FL and MZL, while financing activity raised about $160 million in equity and left the company with an estimated $261 million in cash and an expected runway extending at least to 2028, positioning it to pursue its ambition of establishing ZYNLONTA as a backbone therapy in DLBCL and indolent lymphomas and to target a substantial U.S. peak revenue opportunity.

The most recent analyst rating on (ADCT) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.

ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook

On January 8, 2026, ADC Therapeutics reported preliminary, unaudited 2025 financial figures indicating ZYNLONTA net product revenue of about $73 million for the full year, up modestly from $69.3 million in 2024, and approximately $22 million in the fourth quarter versus $16.4 million a year earlier, with demand in its current third-line-plus DLBCL indication described as broadly stable and cash and cash equivalents of roughly $261 million expected to fund operations at least to 2028. Operationally, the company highlighted strong updated Phase 1b LOTIS-7 data released in December 2025 for ZYNLONTA in combination with glofitamab in relapsed or refractory DLBCL, outlined key upcoming clinical milestones including expected topline Phase 3 LOTIS-5 results in second-quarter 2026 and full LOTIS-5 and LOTIS-7 data by the end of 2026, reported promising early results from investigator-initiated trials in indolent lymphomas, and noted completion of IND-enabling work on a PSMA-targeting ADC, all of which position the company for potential future label expansions and revenue acceleration but leave near-term growth still reliant on its existing ZYNLONTA franchise and successful execution of its clinical and regulatory strategy.

The most recent analyst rating on (ADCT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.